Anindya Mukherjee, Senior Consultant of Medical Oncology at ShardaCare – Healthcity, shared a poll on LinkedIn:
“Hi, will be starting exciting polling sessions of nuances of oncology focussing on clinical take-ways. Looking forward to active participations and thought exchanges with oncologists around the globe.
Answers with evidence will be shared after a day.
Will be starting with head neck cancers.
Poll 1: After KEYNOTE-689, is perioperative pembrolizumab now the new standard for resectable locally advanced head and neck cancers?”
More posts about head and neck cancers.